Aurobindo Pharma share reacted negatively to FDA inspection report of its subsidiary Eugia and is down more than 10% of its recent high. However it is surprising to see no reaction to the news of sale of Eugia. Also the terms are not clear as there is a payment related to 20 years lease.
Anyone tracking it may share the development. Also VP veterans and people of pharmaceutical background are requested to elaborate for general boarders.
Subscribe To Our Free Newsletter |